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Abstract 
We evaluated the rates of survival and cause of revision of seven different brands of cemented 
primary total knee replacement (TKR) in the Norwegian Arthroplasty Register during the years 
1994 to 2009. Revision for any cause, including resurfacing of the patella, was the primary 
endpoint. Specific causes of revision were secondary outcomes. Three posterior cruciate-retaining 
(PCR) fixed modular-bearing TKRs, two fixed non-modular bearing PCR TKRs and two mobile-
bearing posterior cruciate-sacrificing TKRs were investigated in a total of 17 782 primary TKRs. The 
median follow-up for the implants ranged from 1.8 to 6.9 years. Kaplan-Meier 10-year survival 
ranged from 89.5% to 95.3%. Cox’s relative risk (RR) was calculated relative to the fixed modular-
bearing Profix knee (the most frequently used TKR in Norway), and ranged from 1.1 to 2.6. The risk 
of revision for aseptic tibial loosening was higher in the mobile-bearing LCS Classic (RR 6.8 (95% 
confidence interval (CI) 3.8 to 12.1)), the LCS Complete (RR 7.7 (95% CI 4.1 to 14.4)), the fixed 
modular-bearing Duracon (RR 4.5 (95% CI 1.8 to 11.1)) and the fixed non-modular bearing AGC 
Universal TKR (RR 2.5 (95% CI 1.3 to 5.1)), compared with the Profix. These implants (except AGC 
Universal) also had an increased risk of revision for femoral loosening (RR 2.3 (95% CI 1.1 to 4.8), 
RR 3.7 (95% CI1.6 to 8.9), and RR 3.4 (95% CI 1.1 to 11.0), respectively). These results suggest that 
aseptic loosening is related to design in TKR. 
 
 
 
The aim of this study was to investigate the rate of survival and causes of revision for seven brands of 
cemented primary total knee replacement (TKR) registered in the Norwegian Arthroplasty Register 
(NAR) between 1994 and 2009. The brands are the currently and historically among the most 
commonly used both in Norway and around the world1, 2. The study was limited to cemented 
implants without patellar resurfacing, and the data reflect the results of the average surgeon. We 
accept that pooling of data from many surgeons, with different experience, patient volumes and 
skills, may give good external validity but may also hide the effect of a learning curve and any positive 
effect that may be related to high volumes undertaken by some surgeons. 
We also investigated whether survival was brand specific or related to particular types of design. 
Patients and Methods 
Data from patients registered in the NAR during this time were evaluated. The registration of hip 
replacements in the NAR started in 1987 and was expanded to include TKRs and the replacement of 
other joints in 19943, 4. The completeness of the registration was estimated by Espehaug et al5 to be 
99% of all primary TKRs and 97% of all revision procedures between1999 and 2002. Any complete or 
partial removal/exchange of the implant, or insertion of a component (including a patellar 
component), was considered a revision procedure. The unique identification number of all 
Norwegian residents facilitates linking the revisions to the primary operations. 
 All TKRs were cemented and were inserted without patellar components. Differences 
between the designs were predominantly on the tibial side; two  were mobile-bearing TKRs (LCS 
Classic and LCS Complete (DePuy, Warsaw, Indiana), both rotating platform), two were non-modular 
fixed bearing TKRs (AGC Universal and AGC Anatomic; both Biomet, Warsaw, Indiana), and three 
were modular fixed-bearing TKRs (Duracon; Stryker, Portage, Michigan; NexGen; Zimmer, Warsaw, 
Indiana; and Profix; Smith & Nephew, Memphis, Tennessee). The mobile-bearing TKRs were posterior 
cruciate ligament (PCL) sacrificing, and the others were PCL retaining. 
Implant designs not in use after 2004, and those which were used in < 500 cases, were excluded (Fig. 
1). TKRs introduced with computer-navigation were excluded because the technique was not widely 
used for the TKRs which were selected. Posterior-stabilised implants were excluded because of 
relatively low numbers (the Profix Conforming Plus was regarded as posterior stabilised). The 
inclusion criteria were met by 2118 AGC Universal, 1190 AGC Anatomic, 1090 Duracon, 778 NexGen, 
6276 Profix, 2606 LCS Classic and 3714 LCS Complete TKRs. 
Statistical analysis  
Revision for any cause was the primary endpoint. Specific causes for revision and types of revision 
were secondary outcomes. Descriptive analyses were used to assess the baseline characteristics of 
the various brands (Table I). Information on deaths or emigrations up to 31 December 2009 was 
retrieved from the National Population Register. The survival times of unrevised TKRs were taken at 
the last date of observation (date of death or emigration, or 31 December 2009). Median follow-up 
was calculated with the reverse Kaplan–Meier method 6.  Unadjusted survival curves for the various 
brands were constructed using the Kaplan-Meier method, and stopped when < 50 knees remained at 
risk. Survival percentages after five and ten years’ follow-up are reported. Cox’s multiple regression 
model was used to calculate hazard rate ratios (RR), adjusted for potential confounding by age, 
gender, pre-operative diagnosis (osteoarthritis or other diagnoses) and previous knee surgery 
(yes/no). The RR estimates are presented with 95% confidence intervals (CI) and p-values reported 
relative to the Profix TKR, which was the most common TKR in Norway in the last decade. A sub-
analysis was performed to present the risk estimates of the category of design relative to fixed 
modular-bearing designs. We tested the proportional hazards assumption of the Cox model based on 
scaled Schoenfeld residuals.7, 8 With revision for any reason as the endpoint, the assumption was 
found valid for the factors ‘prosthesis brand’ with the Profix implant as the reference brand (p ≥ 0.1) 
and ‘design category’ with fixed modular bearing as the reference category (p ≥ 0.6). Bilateral TKRs 
were included in the study. Although this might imply a violation of the assumption of independent 
observations in the survival analyses, studies have shown that the impact on statistical precision is 
minor for both hip9 and knee replacements.10  
 PASW Statistics version 18 (IBM SPSS , IBM Corporation, Armonk, New York) and R v2.13.0 R 
((The R Foundation for Statistical Computing, http://www.R-project.org 2008) were used for the 
statistical analyses, and p < 0.05 was considered statistically significant. 
 The NAR has approval from the Norwegian Data Inspectorate to collect patient data on 
condition ofbased on a concession  and the a written consent of the patient. 
 
Results 
The study groups did not differ markedly with respect to age, gender, laterality or diagnosis (Table I ). 
The median follow-up ranged from 1.8 to 6.9 years depending on the implant (Table II). The Cox’s 
regression analyses and the Kaplan-Meier curves showed that the Duracon, LCS Classic, LCS Complete 
and AGC Universal brands had a higher risk of revision (RR 1.3 to 2.6) and a statistically significantly 
lower survival (89.5% to 94.0%) than the Profix TKR (95.3%) (Table II, Fig. 2). The NexGen and the 
AGC Anatomic TKR performed in a similar manner to the Profix. A sub-analysis of TKRs performed in 
the latest time period, after 2004, showed a higher risk of revision for the two mobile-bearing 
implants (RR 1.3 (95% CI 1.0 to 1.7)), but not for monobloc implants (RR 1.0 (95% CI 0.7 to 1.4)) 
compared with the fixed-bearing implants. 
There was an increased risk of revision for aseptic tibial loosening in the LCS Classic, LCS Complete 
and the Duracon TKRs compared with the Profix (RR 6.8 (95% CI CI 3.8 to 12.1), RR 7.7 (95% CI 4.1 to 
14.4) and RR 4.5 (95% CI 1.8 to 11.1), respectively) (Table III and Fig. 3a). These implants also had an 
increased risk of revision for aseptic femoral loosening (RR 2.3 (95% CI 1.1 to 4.8), RR 3.7 (95% CI 1.6 
to 8.9) and RR 3.4 (95% CI 1.1 to 11.0), respectively) (Fig. 3b). Also, the AGC Universal TKR had an 
increased risk of revision for aseptic tibial loosening (RR 2.5 (95% CI 1.3 to 5.1)) compared with the 
Profix. The risk of revision due to deep infection was higher for all TKRs except the LCS Classic, 
compared with the Profix (RR from 1.8 to 3.7). The risk of revision due to polyethylene wear and to 
malalignment was higher in the Duracon TKRs (RR 16.6 (95% CI 4.9 to 56.7) and RR 8.7 (95% CI 3.7 to 
20.4), respectively). However, the number of revisions for these reasons was low (n = 10 and n = 10, 
respectively). The LCS Classic had a higher risk of revision due to dislocation of the polyethylene (RR 
3.7 (95% CI 1.2 to 11.1)). The AGC Universal had a higher risk of revision due to pain (RR 2.1 (95% CI 
1.5 to 3.0)) and dislocation of the patella (RR 8.0 (95% CI 1.6 to 39.6)), whereas the LCS Complete and 
LCS Classic had a lower risk of revision due to pain as the only cause of revision (RR 0.4 (95% CI 0.2 to 
0.8)). Insertion of a patellar component was the most frequent revision operation performed for 
pain. 
Using the fixed modular-bearing category as the reference, for the three categories of design we 
found an increased risk of revision due to aseptic loosening of the tibial tray in the mobile-bearing 
(RR 4.8 (95% CI 3.2 to 7.3)) and the monobloc category (RR 1.9 (95% CI 1.1 to 3.3)). Aseptic loosening 
of the femoral component was more common in the mobile-bearing category (RR 2.5 (95% CI 1.4 to 
4.4)). Further, we included only the most used subtypes of the implants in the analysis, but the 
results did not change. 
In order to minimise the effect of a learning curve, we performed a sub-analysis that only included 
TKRs from hospitals having inserted > 100. The risk of revision for aseptic tibial loosening was still 
higher for the LCS Classic (RR 5.8 (95% CI 3.3 to 10.2) and the LCS Complete (RR 6.8 (95% CI 3.6 to 
12.8)) compared with the Profix TKR. The type of cement did not influence survival. The mean 
operating time ranged from 85 minutes for the AGC Anatomic to 105 minutes for the NexGen TKR 
(Table I). 
In order to preclude any time dependency, we analysed the one-year and five-year Kaplan-Meier 
overall survival rates and the Cox’s regression hazard rate ratios. The differences in survival of the 
various brands did not change markedly over time. 
Discussion 
The Duracon, LCS Classic, LCS Complete and AGC Universal brands had lower survival than the Profix, 
whereas the NexGen and AGC Anatomic TKRs did not. Increased risk of revision for aseptic loosening 
of the tibial and femoral components was the major reason for the inferior performance. The AGC 
Universal was more likely to be revised because of pain than the other brands, and LCS Complete and 
LCS Classic were less likely to be revised for this reason. The risk of revision for deep infection was 
higher for all brands, except the LCS Classic, than for the Profix. 
The implants with a higher risk of aseptic loosening represent different design principles, so no 
common thread was apparent. For example, the fixed non-modular bearing AGC Universal was 
inferior to the Profix, but the AGC Anatomic was not.  
Revision because of pain was rare with mobile-bearing implants, which is consistent with the theory 
that rotation of the mobile bearing improves patellar tracking.11 The AGC Anatomic, with right/left 
femoral components, has replaced the AGC Universal, and its good results are consistent with data 
from the Australian Arthroplasty Registry showing similar revision rates for monoblock and fixed-
bearing TKRs after ten years.2 
The risk of revision due to dislocation of the polyethylene bearing was higher for the LCS Classic than 
for the Profix, but not for the LCS Complete. In our study most of the mobile-bearing LCS TKRs 
sacrificed the PCL, whereas the fixed modular and fixed non-modular TKRs were PCL retaining (Table 
I). 
This study focused on the causes of revision and found the highest risk of revision to be in the LCS 
TKRs, for both aseptic tibial and femoral loosening. Other studies have shown good survival and 
clinical results of mobile-bearing designs,11-14 but these studies did not compare mobile with fixed 
bearings. The inferior results of the mobile-bearing TKRs in our study are consistent with data from 
the Australian Joint Replacement Registry2 and from the Southern California Permanente Medical 
Group.15, 16 
The aim of the mobile-bearing design was to combine low constraint forces with low contact 
stresses, theoretically reducing polyethylene wear and aseptic loosening.17 Early fixed-bearing 
designs had unsatisfactory function and range of movement, and it was claimed that the 
biomechanics of the mobile-bearing design were closer to those of a normal knee, and would 
improve function and longevity.18 Dislocation of the polyethylene was a problem in the early years of 
the mobile-bearing TKR, but as the technique and instruments evolved, this complication became 
rare.19 However, there is no strong evidence that any mobile-bearing design is superior to a fixed 
bearing with regard to pain, function, range of movement or failure rate.20, 21 It is claimed that wear 
of the polyethylene in the modular fixed bearing and the mobile bearing at the tibial interface may 
lead to peri-prosthetic osteolysis and loosening.22, 23 This so-called backside wear is eliminated in the 
fixed non-modular (monobloc) design, but the modularity option is lost. The monobloc design has 
excellent survival in several studies,24-27 but most surgeons prefer the modular fixed bearing. 
A retrieval study evaluating 48 mobile bearings concluded that wear was as severe as that in fixed 
modular-bearing designs.23 Similar polyethylene wear was found for a mobile-bearing rotating 
platform and  a fixed modular bearing in an in vitro study.28 Another in vitro study, however, 
concluded that the wear rate of the fixed bearing was four times higher than for the rotating 
platform,29 but in two meta-analyses no differences in the incidence of radiolucent lines or clinical 
outcome were found.21, 30 Recent reports from the NAR did not show differences in pain, function or 
survival for the LCS Classic, or survival for the LCS Complete, compared to the AGC Universal TKR.31, 32 
Differences in geometry and undersurface texture in the two mobile-bearing TKRs might explain why 
they differ in outcome.33 All the mobile-bearing TKRs in this study were ‘no keel’ subtypes, and there 
might have been less resistance to rotational forces with this design compared to those with a keel 
(Table IV). The higher risk of revision for aseptic loosening of the tibial and femoral components in 
the LCS Classic and LCS Complete must be further investigated, focusing on wear and shear forces at 
the prosthesis–cement–bone interfaces. 
The inferior results reported here for the Duracon TKR differ from those reported from the Australian 
Arthroplasty Register.2 A possible explanation could be that in 2005 the Duracon TKR was introduced 
in one geographical region of Norway as a result of a tender process, and therefore the local 
surgeons were obliged to go through a learning process. 
In conclusion, differences in the causes of revision were brand specific. The assumption that fixed 
modular-bearing implants are more at risk of loosening due to polyethylene wear than mobile-
bearing designs was not supported by this study. 
 
Supplementary material 
A table detailing the use of subtypes of implants within each brand and two Kaplan-Meier survival 
curves showing cumulative survival at i) one and ii) five years. 
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Figure 1. Selection chart showing inclusions and exclusions of cases. There may be more than one exclusion criteria 
per case (* rare combinations of implants: Profix mobile-bearing (n = 12), AGC Dual (52), various combinations of 
LCS (n = 565)). 
 Figure 2. Kaplan-Meier survival analysis of the various brands with revision for any reason as the 
endpoint. 
 
 
 
 Figure 3a 
 Figure 3b 
Figure 3a and 3b show Kaplan-Meier analyses of the various brands with a) tibial and b) femoral 
loosening as the endpoint. 
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Supplementary material 
 
 
Figure i 
 Figure ii 
 
Figure i and ii. Kaplan-Meier curves showing survivorship by brand at i) one year and ii) five years, 
hazard rates significantly different from Profix. 
 
  
 
Table i. Subtypes registered for each prosthesis brand and number revised 
 
Subtype Tibia Femur Revised 
NexGen    
Precoat PMMA stemmed 379  8 
Precoat PMMA pegged 5  1 
Option 391  16 
Precoat CR  31 2 
Option CR  594 22 
Option CRA  4 0 
CR Flex Option  140 1 
CR Flex gender-specific  6 0 
    
LCS    
PCR porocoat 1  0 
PCR textured 11  5 
Rotating platform porocoat 7  0 
Rotating platform textured 2539  128 
Rev rotating platform porocoat 45  2 
Mod rev 3  0 
Porocoat  121 5 
Textured  2474 128 
Rev porocoat  3 0 
Mod rev  8 0 
    
AGC    
V2 interlok 3252  147 
Interlok 61  2 
Anatomic porous  2 0 
Anatomic interlok  1188 29 
Universal interlok  57 3 
V2 interlok  2061 118 
    
LCS Complete    
No keel MBT 3676  99 
With keel MBT 1  0 
MBT revision 20  1 
Small, standard, large (+)  3609 94 
Mod/revision-unconstrained s,m,st,l (+)  5 0 
    
Profix    
Non-porous 6276 6276 195 
    
Duracon    
Porous with screw fixation 4  0 
Porous with stem 3  0 
Porous/resurf 2  0 
Cruciform/porous 110  13 
Univ/porous 2  0 
Univ/non-porous 9  2 
Cruciform/non-porous 904  38 
Bead, PCA 14  0 
Resurf, PCA 36  3 
Cruciform, beaded 1  0 
Porous  166 14 
Non-textured  780 36 
Porous Modular  12 0 
Non-textured Modular  121 5 
Monolithic(PS)  3 0 
 
 
